查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1983844

失眠治疗市场：按药物类别、剂型、给药途径、最终用户和分销管道分類的全球市场预测，2026-2032年

Insomnia Drugs Market by Drug Class, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年失眠治疗市场价值 32.4 亿美元，预计到 2026 年将成长至 34.3 亿美元，复合年增长率为 5.96%，到 ​​2032 年将达到 48.7 亿美元。

主要市场统计数据
基准年 2025 32.4亿美元
预计年份：2026年 34.3亿美元
预测年份 2032 48.7亿美元
复合年增长率 (%) 5.96%

简要概述现代失眠治疗趋势中的治疗方法创新、临床挑战和商业性因素。

在科学进步、患者期望不断变化以及监管审查日益严格的推动下，失眠治疗市场正经历快速变化。本执行摘要阐述了影响药物研发、临床实务、分销和支付方参与等相关相关人员当前及近期决策的关键主题。本概述全面分析了治疗方法创新、不断变化的消费者模式以及支持治疗交付的基础设施，为寻求调整投资以把握新兴机会的领导者提供了清晰的切入点。

分析了正在重塑失眠治疗药物的研发和分销的、模式转移的临床进展、支付方的期望以及药物输送创新。

失眠治疗领域正经历一场变革，其驱动力包括作用机制的创新、安全性期望的提高以及数位诊疗路径的发展。针对Orexin受体的新型化合物正在重塑关于疗效和次日起效的临床讨论，促使临床医生重新评估处方模式和风险获益权衡。同时，旨在改善起效时间、持续时间和耐受性的药物科学进展正在影响产品在门诊和住院环境中的定位。

2025 年的关税调整和贸易趋势将如何推动失眠药物供应链的重新设计、购买多元化以及对整个价值链韧性的投资？

2025年实施的政策和贸易措施，包括关税调整，为製药企业和经销商的全球供应链规划引入了新的变数。这些措施影响了某些进口原料药、辅料和成品的成本基础，促使采购团队重新评估筹资策略和紧急储备。为此，许多企业正在加速供应商网路多元化，并转向近岸外包，以降低贸易波动风险。

全面的细分情报揭示了不同治疗领域之间的细微差异、製剂和给药途径的变化、分销趋势以及最终用户模式，从而帮助制定有针对性的策略。

细分市场分析揭示了影响不同治疗领域、剂型、给药途径、分销管道和终端用户环境的药物价值和需求的因素存在差异。药物类别包括抗组织胺、苯二氮平类、褪黑素受体促效剂、非苯二氮平类药物和Orexin受体拮抗剂。在非苯二氮平类药物中，具有重要临床意义的药物如依佐匹克隆、Zaleplon和Zolpidem在起效时间和半衰期方面表现出不同的特征，从而影响产品定位。同时，Orexin受体拮抗剂，包括达利德生、伦博雷生和苏沃雷生，在处方医师决策中，其疗效和耐受性方面存在独特的争议。这些差异导致了不同的临床定位和促销策略，有些药物更适合短期症状管理，而有些则更适合维持治疗。

失眠药物在美洲、欧洲、中东和非洲以及亚太地区面临不同的区域趋势和法规，因此需要采取适应性的取得和分销策略。

区域趋势持续影响产品策略、监管应对方案和分销网络设计。在美洲，临床实践模式以及公立和私人保险公司之间的互动影响着处方药的上市，而数位医疗和远距药事照护模式的采用则扩大了门诊病人范围并提升了病人参与。美洲市场的进入考量通常着重于展现产品在实际应用功能和安全性方面的差异化优势，以确保获得临床医生和保险公司的青睐。

我们透过强调治疗差异化、数位化合作、生命週期管理和证据产生的竞争和企业策略，确保临床和商业性优势。

主要企业之间的竞争特征是：有针对性的研发投入、建立合作伙伴关係以及专注于生命週期管理，旨在维持临床意义。每家公司都利用其临床差异化优势，例如给药后第二天即可改善认知功能以及最大限度地降低成瘾风险，从而使后期研发和上市产品更受处方医生和支付方的青睐。製药开发商与数位医疗供应商之间的策略合作日益普遍，从而能够提供结合药物疗法和行为干预的解决方案，以解决用药依从性和长期治疗效果问题。

为产业领导者提供实用的策略指南，以协调证据产生、数位整合、弹性供应链和个人化商业化，从而建立可持续的竞争优势。

产业领导者应优先考虑整合式方法，将临床差异化与切实可行的打入市场策略和稳健的供应链设计相结合。首先，他们应投资于有针对性的证据生成，以证明药物的相对疗效、患者报告结果和真实世界安全性，从而支持药物的推广应用并与支付方展开对话。其次，他们应加强与数位医疗服务提供者的合作，建立整合式照护路径，以提高患者的用药依从性并扩大市场覆盖范围，尤其是在门诊和居家照护领域。此类整合式服务将增强对临床医生和支付方的价值提案。

为了确保解释的准确性，我们采用了严谨的多方面调查方法，该方法包括与相关人员的访谈、监管审查、临床数据的整合以及供应链风险评估。

本研究采用跨学科调查方法，结合定性和定量证据来源，旨在阐明失眠治疗的现状。第一阶段包括对关键相关人员进行结构化访谈，这些利害关係人包括临床专家、药物采纳决策者、采购经理和分销合作伙伴，以了解观点。第二阶段利用同侪审查文献、监管指导文件、临床试验註册资讯和上市公司资讯披露讯息，全面检验临床和监管趋势。

结论整合了临床差异化、循证投资、灵活的供应策略和以管道为中心的商业化，以产生可持续的影响。

总之，失眠治疗领域正受到机制特异性临床进展、安全性和日常生活功能预期变化以及分销和医疗服务模式转型等因素的重塑。将产品开发与差异化临床特征相结合、投资于真实世界数据并采用灵活的生产和筹资策略的相关人员，将更有能力应对商业性和监管方面的复杂挑战。此外，整合数位健康方法并制定针对特定管道的商业化计划，对于扩大治疗覆盖范围和提高门诊及居家照护环境中的用药依从性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：失眠治疗市场：依药物类别划分

  • 抗组织胺药
  • 苯二氮平类药物
  • 褪黑素受体促效剂
  • 非苯二氮平类药物
    • 依佐匹克隆
    • Zaleplon
    • Zolpidem
  • Orexin受体拮抗剂
    • 达利德雷桑
    • 伦博雷桑
    • 斯沃雷桑特

第九章 依剂型分類的失眠治疗药物市场

  • 胶囊
  • 注射药物
  • 口服悬浮液
  • 舌下片
  • 药片

第十章：失眠治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 舌下
  • 经皮

第十一章：失眠治疗市场：依最终使用者划分

  • 门诊部
  • 诊所
  • 居家照护
  • 医院
    • 私立医院
    • 公立医院

第十二章：失眠治疗市场：依通路划分

  • 药局
  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
    • 通用B2C平台
    • 厂商直销网站
    • 远距药事照护服务
  • 零售药房
    • 连锁药局
    • 独立经营药房
    • 超级市场内的药房

第十三章：失眠治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 失眠治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 失眠治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国失眠治疗市场

第十七章：中国失眠治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Biogen SA
  • Cadila Healthcare Ltd.
  • Dr.Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Flynn Pharma Limited
  • Glenmark Pharmaceuticals Ltd.
  • Idorsia Pharmaceuticals Ltd.
  • LA Herbal（India）
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Minerva Neurosciences, Inc.
  • Neuracle Lifesciences Private Limited
  • Neurim Pharmaceuticals LTD.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi Group
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.
  • Wockhardt Limited
Product Code: MRR-F6513A06BE94

The Insomnia Drugs Market was valued at USD 3.24 billion in 2025 and is projected to grow to USD 3.43 billion in 2026, with a CAGR of 5.96%, reaching USD 4.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.24 billion
Estimated Year [2026] USD 3.43 billion
Forecast Year [2032] USD 4.87 billion
CAGR (%) 5.96%

A concise contextual introduction framing therapeutic innovation, clinical pressures, and commercial drivers that shape the modern insomnia treatment landscape

The insomnia drugs landscape is undergoing rapid evolution driven by scientific advances, shifting patient expectations, and intensifying regulatory attention. This executive summary introduces the critical themes that shape current and near-term decision-making for stakeholders across pharmaceutical development, clinical practice, distribution, and payer engagement. The overview synthesizes therapeutic innovations, changing consumption patterns, and the infrastructure supporting treatment delivery, offering a clear entry point for leaders seeking to align investments with emerging opportunities.

Importantly, this introduction situates insomnia within a broader healthcare context where comorbid psychiatric and cardiometabolic conditions influence both therapeutic choices and adherence. It highlights how pharmacological differentiation, safety profiles, and convenience of administration increasingly determine clinician preference and patient uptake. The section sets expectations for the subsequent analysis by outlining methodological rigor and the multi-dimensional lens-clinical, regulatory, commercial-used to interpret trends. Readers are invited to proceed with a focus on strategic implications rather than historical volume metrics, as the subsequent sections prioritize actionable insights that support portfolio and market-access decisions.

An analysis of paradigm-shifting clinical advances, payer expectations, and care-delivery innovations that are reshaping insomnia drug development and adoption

The insomnia therapeutics environment is experiencing transformative shifts shaped by innovation in mechanism of action, heightened safety expectations, and digital-enabled care pathways. Novel compounds targeting orexin receptors have recalibrated clinical conversations about efficacy and next-day functioning, prompting clinicians to reassess prescribing patterns and risk-benefit trade-offs. Concurrently, advances in formulation science-aimed at improving onset, duration, and tolerability-are influencing how products are positioned across ambulatory and institutional settings.

Meanwhile, payer scrutiny and regulatory guidance are prompting manufacturers to demonstrate differentiated value through real-world evidence and comparative-effectiveness studies. Digital therapeutics and remote patient monitoring are redefining adjunctive treatment models, enabling stepped-care approaches that combine behavioral and pharmacologic interventions. Additionally, patient-centric packaging and alternative routes of administration are gaining attention as adherence drivers. Collectively, these shifts are altering competitive dynamics, funneling investment into targeted R&D, and encouraging strategic partnerships that accelerate time-to-clinic for next-generation insomnia solutions.

How 2025 tariff adjustments and trade dynamics are prompting supply chain redesigns, procurement diversification, and resilience investments across the insomnia drug value chain

Policy and trade actions, including tariff adjustments implemented in 2025, have introduced new variables into global supply chain planning for pharmaceutical manufacturers and distributors. These measures have affected the cost base for certain imported active pharmaceutical ingredients, excipients, and finished formulations, prompting procurement teams to reassess sourcing strategies and contingency inventories. In response, many organizations have accelerated diversification of supplier networks and increased emphasis on nearshoring to reduce exposure to trade-related volatility.

In addition, the tariff landscape has intensified scrutiny of cost-to-serve calculations across distribution channels. Hospital pharmacies and large retail chains have re-evaluated procurement agreements and inventory management protocols to mitigate margin compression. Meanwhile, manufacturers have revisited manufacturing footprints and supply chain resilience investments, prioritizing flexibility in batch sizes and multi-site qualification. Regulatory compliance considerations and quality assurance requirements continue to shape these adjustments, and companies are increasingly balancing tariff-driven cost pressures with commitments to reliability and therapeutic integrity.

Comprehensive segmentation intelligence revealing therapeutic class nuances, formulation and administration distinctions, distribution dynamics, and end-user patterns that inform targeted strategies

Segmentation analysis reveals differentiated drivers of value and demand across therapeutic class, formulation, route of administration, distribution channel, and end-user settings. The drug class dimension encompasses antihistamines, benzodiazepines, melatonin receptor agonists, non-benzodiazepines, and orexin receptor antagonists; within the non-benzodiazepine category, clinically relevant agents such as eszopiclone, zaleplon, and zolpidem demonstrate varying profiles of onset and half-life that influence positioning, while orexin receptor antagonists including daridorexant, lemborexant, and suvorexant have introduced a distinct efficacy and tolerability conversation into prescriber decision-making. These differences drive divergent clinical narratives and promotional strategies, with some classes remaining more attractive for short-term symptom control and others suited for maintenance therapy considerations.

Formulation choices-ranging from capsules, injectables, oral suspensions, sublingual tablets, to tablets-are shaping product differentiation and patient preference, as ease of use and onset characteristics become competitive levers. Route-of-administration distinctions, including intravenous, oral, sublingual, and transdermal options, further influence hospital versus outpatient utilization and the feasibility of certain therapeutic approaches in primary care or acute settings. Distribution channel segmentation highlights the role of drug stores, hospital pharmacies, online pharmacies, and retail pharmacies in shaping access and adherence; within hospital pharmacies, private and public institutions exhibit differing procurement behaviors, while online pharmacies segment into general B2C platforms, manufacturer direct sites, and telepharmacy services, each presenting unique regulatory and commercial dynamics. Retail pharmacy variations-chain, independent, and supermarket pharmacies-affect promotional reach and point-of-sale engagement strategies. End-user segmentation across ambulatory care centers, clinics, home care, and hospitals underscores divergent care pathways; hospitals themselves differentiate into private and public entities with distinct formulary processes and procurement cycles. By integrating these segmentation lenses, stakeholders can better tailor clinical development, marketing, and distribution tactics to match the nuanced needs of targeted prescribers and patients.

Regional dynamics and regulatory diversity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that require adaptive access and distribution strategies for insomnia therapies

Regional dynamics continue to shape product strategy, regulatory planning, and distribution network design. In the Americas, clinical practice patterns and the interplay between private and public payers influence formulary access, while digital health adoption and telepharmacy models are expanding outpatient reach and patient engagement. Market entry considerations in the Americas often revolve around demonstrating differentiation in real-world functioning and safety to secure favorable positioning with both clinicians and payers.

Within Europe, Middle East & Africa, heterogeneous regulatory frameworks and procurement environments demand adaptive market-access strategies that account for national formularies, public hospital procurement, and private-sector variability. Clinicians across these geographies weigh long-term tolerability and comorbidity profiles heavily in prescribing decisions, and reimbursement pathways can vary significantly between public and private systems. In the Asia-Pacific region, rapid uptake of telemedicine, diverse reimbursement mechanisms, and evolving domestic manufacturing capabilities present both opportunities and complexity. Stakeholders are prioritizing localized evidence generation, regulatory alignment strategies, and partnerships with regional distributors to navigate procurement practices and expedite adoption across public and private healthcare settings. Across all regions, supply chain resilience, local regulatory engagement, and culturally informed patient education remain essential components of successful commercialization.

Competitive and corporate maneuvers emphasizing therapeutic differentiation, digital collaborations, lifecycle management, and evidence generation to secure clinical and commercial advantage

Competitive behavior among leading organizations is characterized by targeted R&D investment, alliance formation, and a focus on lifecycle management aimed at sustaining clinical relevance. Companies are leveraging clinical differentiation, such as improved next-day cognitive profiles and minimized dependency risks, to position late-stage and marketed products more favorably with prescribers and payers. Strategic collaborations between pharmaceutical developers and digital health vendors are becoming more commonplace, enabling combined pharmacologic and behavioral offerings that address adherence and long-term outcomes.

Additionally, some manufacturers are optimizing commercialization by tailoring packaging, patient-support programs, and specialty pharmacy partnerships to specific distribution channels and end-user settings. Mergers, acquisitions, and licensing agreements remain tactical options for expanding portfolios or acquiring differentiated mechanisms of action. Across the competitive landscape, there is increasing emphasis on generating post-approval evidence, including real-world studies and registries, to substantiate value claims and support reimbursement negotiations. Operationally, firms are investing in supply chain flexibility and regulatory expertise to accelerate market entry across multiple geographies while maintaining high standards of quality and safety.

Actionable strategic directives for industry leaders to align evidence generation, digital integration, resilient supply chains, and tailored commercialization for sustainable advantage

Industry leaders should prioritize an integrated approach that aligns clinical differentiation with pragmatic market-access strategies and resilient supply chain design. First, invest in targeted evidence generation that demonstrates comparative effectiveness, patient-reported outcomes, and real-world safety to support formulary inclusion and payer dialogues. Secondly, pursue partnerships with digital health providers to create bundled care pathways that improve adherence and extend market reach, particularly in outpatient and home-care settings. Such combined offerings will enhance value propositions to both clinicians and payers.

Concurrently, optimize manufacturing and procurement by diversifying suppliers and qualifying alternate sites to mitigate exposure to trade and tariff-related disruption. Strengthen engagement with hospital formulary committees through tailored value dossiers and locally relevant real-world data to expedite acceptance in both private and public institutions. Finally, tailor commercialization strategies by aligning formulation and route preferences with distribution channel capabilities and end-user needs, ensuring that messaging addresses both efficacy and daily-life impact. Together, these actions create a coherent plan that balances short-term access priorities with long-term brand sustainability.

A rigorous multi-source research methodology integrating stakeholder interviews, regulatory review, clinical synthesis, and supply chain risk assessment to ensure interpretive rigor

This research employed a multi-disciplinary methodology combining qualitative and quantitative evidence sources to build a robust understanding of the insomnia therapeutic landscape. Primary research involved structured interviews with key stakeholders, including clinical experts, formulary decision-makers, procurement leads, and distribution partners, to capture frontline perspectives on adoption drivers, safety concerns, and operational constraints. Secondary research utilized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate clinical and regulatory trends.

Analytical techniques included comparative clinical profiling, segmentation mapping across therapeutic class, formulation, route of administration, distribution channel, and end-user settings, and supply chain risk assessment focused on recent policy and tariff developments. Care was taken to validate insights through cross-referencing multiple independent sources and through iterative expert review. The methodology emphasizes transparency in data sourcing and interpretive rigor, ensuring that conclusions reflect current practice patterns and the prevailing regulatory landscape rather than speculative projections.

A concluding synthesis emphasizing clinical differentiation, evidence investment, flexible supply strategies, and channel-focused commercialization to drive sustainable impact

In conclusion, the insomnia drugs domain is being reshaped by mechanism-specific clinical advances, evolving expectations for safety and daily functioning, and shifts in distribution and care-delivery models. Stakeholders who align product development with differentiated clinical profiles, invest in real-world evidence, and adopt flexible manufacturing and procurement strategies will be better positioned to navigate commercial and regulatory complexity. Additionally, integrating digital health modalities and designing channel-specific commercialization plans will be critical to expanding reach and improving adherence in outpatient and home-care settings.

Moving forward, decision-makers should maintain a dual focus on near-term access imperatives-such as formulary positioning and supply chain resilience-and longer-term investments in evidence that supports differentiated value. By doing so, organizations can create durable competitive advantage while responding responsibly to payer and clinician priorities. The subsequent actionable recommendations and tailored engagement with sales and advisory resources can help translate these strategic directions into operational plans that deliver measurable outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Drugs Market, by Drug Class

  • 8.1. Antihistamines
  • 8.2. Benzodiazepines
  • 8.3. Melatonin Receptor Agonists
  • 8.4. Non-Benzodiazepines
    • 8.4.1. Eszopiclone
    • 8.4.2. Zaleplon
    • 8.4.3. Zolpidem
  • 8.5. Orexin Receptor Antagonists
    • 8.5.1. Daridorexant
    • 8.5.2. Lemborexant
    • 8.5.3. Suvorexant

9. Insomnia Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Injectables
  • 9.3. Oral Suspensions
  • 9.4. Sublingual Tablets
  • 9.5. Tablets

10. Insomnia Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Sublingual
  • 10.4. Transdermal

11. Insomnia Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Insomnia Drugs Market, by Distribution Channel

  • 12.1. Drug Stores
  • 12.2. Hospital Pharmacies
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Online Pharmacies
    • 12.3.1. General B2C Platforms
    • 12.3.2. Manufacturer Direct Sites
    • 12.3.3. Telepharmacy Services
  • 12.4. Retail Pharmacies
    • 12.4.1. Chain Pharmacies
    • 12.4.2. Independent Pharmacies
    • 12.4.3. Supermarket Pharmacies

13. Insomnia Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Insomnia Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Insomnia Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Insomnia Drugs Market

17. China Insomnia Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alembic Pharmaceuticals Limited
  • 18.6. Astellas Pharma Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Biogen SA
  • 18.9. Cadila Healthcare Ltd.
  • 18.10. Dr.Reddy's Laboratories Limited
  • 18.11. Eisai Co., Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. Flynn Pharma Limited
  • 18.14. Glenmark Pharmaceuticals Ltd.
  • 18.15. Idorsia Pharmaceuticals Ltd.
  • 18.16. LA Herbal (India)
  • 18.17. Mallinckrodt Pharmaceuticals
  • 18.18. Merck & Co., Inc.
  • 18.19. Minerva Neurosciences, Inc.
  • 18.20. Neuracle Lifesciences Private Limited
  • 18.21. Neurim Pharmaceuticals LTD.
  • 18.22. Orexo AB
  • 18.23. Pfizer Inc.
  • 18.24. Purdue Pharma L.P.
  • 18.25. Sanofi Group
  • 18.26. Sun Pharmaceutical Industries Limited
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Vanda Pharmaceuticals Inc.
  • 18.29. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GCC INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. GCC INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 276. G7 INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 278. G7 INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. G7 INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. G7 INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 288. NATO INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. NATO INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. NATO INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. NATO INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)